The company uses a proprietary algorithm, PREDICT(TM), to model the 3D structure of any GPCR target and advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target. Predix also has an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery. The company's focus is on developing small-molecule drugs to treat anxiety, Alzheimer's disease, pulmonary arterial hypertension, and other diseases.